Published in ANZ J Surg on January 01, 2013
The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses. J Clin Cell Immunol (2015) 0.78
Developments in Intralesional Therapy for Metastatic Melanoma. Cancer Control (2016) 0.77
In vitro combination therapy using low dose clotrimazole and photodynamic therapy leads to enhanced killing of the dermatophyte Trichophyton rubrum. BMC Microbiol (2014) 0.77
Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget (2016) 0.76
Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell Death Dis (2017) 0.75
Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol (2007) 0.95
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Ann Surg Oncol (2014) 0.85
Burnout in Australasian Younger Fellows. ANZ J Surg (2009) 0.83
Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Res (2013) 0.80
Can cancer registries show whether treatment is contributing to survival increases for melanoma of the skin at a population level? J Eval Clin Pract (2013) 0.75
Erratum: XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Sci Rep (2015) 0.75
Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy. Oncol Rep (2013) 0.75